# US 2016/0251374 A1 · Filamin a binding anti-inflammatory and analgesic

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251374 A1
- Document ID: US20160251374A1
- Status: Published application
- Kind: A1
- Application number: 15/156,898
- Filed: 2016-05-17
- Published: 2016-09-01
- Earliest claimed: 2007-11-02
- Inventors: Lindsay Burns Barbier; Hoau-Yan Wang; Han-Horng Lin; Andrei Blasko
- Web page: https://patentgrep.com/patent/US20160251374A1

## CPC

- C07D 498/10: Spiro-condensed systems
- C07D 471/10: Spiro-condensed systems
- C07D 513/10: Spiro-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A compound or its pharmaceutically acceptable salt, optionally including both individual enantiomeric forms, a racemate, diastereomers and mixtures thereof, composition and method are disclosed that can provide analgesia and reduce inflammation. A contemplated compound has a structure that corresponds to Formula A, wherein the R group substituents, d, e, f, k, n, m, D, E, F, K, G, P, Q, W, and Z are defined within.

## Claims

### Claim 1

A compound that corresponds in structure to Formula A or a pharmaceutically acceptable salt thereof, optionally including both individual enantiomeric forms, a racemate, diastereomers and mixtures thereof
wherein
Q is CHR9 or C(O);
Z is CHR10 or C(O), but only one of Q and Z is C(O);
each of m and n is zero or one and the sum of m+n is 1 or 2;
G, P and W are selected from the group consisting of NR20, NR2, NR7, S and O, where R7 and R2 are the same or different and are H, C(H)v(D)h where each of v and h is 0, 1, 2 or 3 and v+h=3, C(H)q(D)r-aliphatic C1-C11 hydrocarbyl where each of q and r is 0, 1, or 2 and q+r=0, 1 or 2, aliphatic C1-C12 hydrocarbyl sulfonyl or aliphatic C1-C12 hydrocarboyl, and R20 is X-circle A-R1 as defined hereinafter, with the provisos that
i) only one of G, P and W is NR20,
ii) one of G, P and W must be NR20,
iii) P is NR2 when other than NR20,
iv) one of G and W is other than NR2 or NR7 in which R2 or R7 is H or an aliphatic C1 hydrocarbyl when (a) the sum of m+n is 1 and (b) the other of G and W is NR20, NR2, or NR7 bonded to a Z or Q, respectively, that is C(O), and
v) P is NR2 in which R2 is other than —S(O)2C1-C3-hydrocarbyl when (a) the sum of m+n is 1 and the Q or Z present is CH2, (b) the G or W that is not NR20 is O, and (c) R20 is —S(O)2phenyl-R1, where R1 is H, C1-C3-hydrocarbyl or halogen;
X is SO2, C(O), CH2, CD2, OC(O), NHC(NH) or NHC(O);
each of d, e, f and k is either zero or one and the sum of (d+e+f+k)=2, e is zero when d is zero, and k is zero when f is zero;
D and F are the same or different and are CH or CD;
E and K are the same or different and are CH2, CHD or CD2;
circle A is an aromatic or heteroaromatic ring system containing one ring or two fused rings;
R1 represents up to three substituent groups that themselves are the same or different, R1a, R1b, and R1c,
wherein each of those three groups, R1a-c, is separately selected from the group consisting of H, C1-C6 hydrocarbyl, C1-C6 hydrocarbyloxy, C1-C6 hydrocarbyloxycarbonyl, trifluoromethyl, trifluoromethoxy, C1-C7 hydrocarboyl, hydroxy-, trifluoromethyl- or halogen-substituted C1-C7 hydrocarboyl, C1-C6 hydrocarbylsulfonyl, C1-C6 hydrocarbyloxysulfonyl, halogen, nitro, phenyl, cyano, carboxyl, C1-C7 hydrocarbyl carboxylate, carboxamide or sulfonamide wherein the amido nitrogen in either group has the formula NR3R4 wherein R3 and R4 are the same or different and are H, C1-C4 hydrocarbyl, or R3 and R4 together with the depicted nitrogen form a 5-7-membered ring that optionally contains 1 or 2 additional hetero atoms that independently are nitrogen, oxygen or sulfur, MAr, where M is —CH2—, —O— or —N═N— and Ar is a single-ringed aryl or heteroaryl group, and NR5R6 wherein R5 and R6 are the same or different and are H, C1-C4 hydrocarbyl, C1-C4 acyl, C1-C4 hydrocarbylsulfonyl, or R5 and R6 together with the depicted nitrogen form a 5-7-membered ring that optionally contains 1 or 2 additional hetero atoms that independently are nitrogen, oxygen or sulfur;
R8, R9, and R10 are each H, or two of R8, R9, and R10 are H and one is a C1-C8 hydrocarbyl group that is unsubstituted or is substituted with up to three atoms that are the same or different and are oxygen or nitrogen atoms;
R11, R12, R13 and R14 are all H, or R11 and R13 are H and R12 and R14 are H or D, or one of the pair R11 and R12 or the pair R13 and R14 together with the depicted ring form a saturated or unsaturated 6-membered ring, and the other pair are each H or they are H and D as recited herein.

### Claim 2 (depends on 1)

The compound or its pharmaceutically acceptable salt according to claim 1, wherein said compound corresponds in structure to a formula selected from the group consisting of:

### Claim 3 (depends on 1)

The compound or its pharmaceutically acceptable salt according to claim 1 that corresponds in structure to Formula B, optionally including both individual enantiomeric forms, a racemate, diastereomers and mixtures thereof
wherein
G and W are selected from the group consisting of NR20, NR7, S and O, where R2 and R7 are the same or different and are H, C(H)v(D)h where each of v and h is 0, 1, 2 or 3 and v+h=3, C(H)q(D)r-aliphatic C1-C11 hydrocarbyl where each of q and r is 0, 1, or 2 and q+r=0, 1 or 2, aliphatic C1-C12 hydrocarbyl sulfonyl or aliphatic C1-C12 hydrocarboyl, and R20 is X-circle A-R1, with the provisos that:
i) only one of G or W is NR20,
ii) that one of G and W must be NR20,
iii) the G or W that is not NR20 is other than NR2 or NR7 in which R2 or R7 is H or an aliphatic C1 hydrocarbyl when (a) the sum of m+n is 1 and (b) the G or W that is NR20 is bonded to a Z or Q, respectively, that is C(O), and
iv) R2 of the depicted NR2 is other than —S(O)2C1-C3-hydrocarbyl when (a) the sum of m+n is 1 and the Q or Z present is CH2, (b) the G or W that is not NR20 is O, and (c) R20 is —S(O)2phenyl-R1, where R1 is H, C1-C3-hydrocarbyl or halogen.

### Claim 4 (depends on 3)

The compound or its pharmaceutically acceptable salt according to claim 3, wherein said compound corresponds in structure to Formula I
wherein D and F are the same or different and are CH2, CHD or CD2, and W, X, Z, Q, n, m, circle A, R1, R2, R8 and the R groups therein defined are as described previously, except that i) R2 of the depicted NR2 is other than —S(O)2C1-C3-hydrocarbyl when (a) the sum of m+n is 1 and the Q or Z present is CH2, (b) the G or W that is not NR20 is O, and (c) R20 is —S(O)2phenyl-R1, where R1 is H, C1-C3-hydrocarbyl or halogen, and ii) W is other than NR2 or NR7 in which R2 or R7 is H or an aliphatic C1 hydrocarbyl when (a) the sum of m+n is 1 and (b) Z is C(O).

### Claim 5 (depends on 4)

The compound or its pharmaceutically acceptable salt according to claim 4, wherein X is C(O), CH2, CD2, or SO2.

### Claim 6 (depends on 4)

The compound or its pharmaceutically acceptable salt according to claim 4, wherein W is NR7, S or O.

### Claim 7 (depends on 4)

The compound or its pharmaceutically acceptable salt according to claim 4, wherein circle A is selected from the group consisting of phenyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl (1,3,5-triazinyl, 1,2,4-triazinyl and 1,2,3-triazinyl), furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, naphthyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, isobenzothiophenyl, benzoxazolyl, benzisoxazole, quinolyl, isoquinolyl, quinazolyl, cinnolinyl, quinoxalinyl, naphthyridinyl, and benzopyrimidinyl.

### Claim 8 (depends on 4)

The compound or its pharmaceutically acceptable salt according to claim 4, wherein one of Q and Z is CH2 and the other is absent.

### Claim 9 (depends on 4)

The compound or its pharmaceutically acceptable salt according to claim 4, wherein said compound corresponds in structure to a formula selected from the group consisting of:

### Claim 10 (depends on 3)

The compound or its pharmaceutically acceptable salt according to claim 3, wherein said compound corresponds in structure to Formula II
wherein D and F are the same or different and are CH2, CHD or CD2, and X, W, circle A, R1, R2 and the R groups therein defined are as described previously, except that R2 of the depicted NR2 is other than —S(O)2C1-C3-hydrocarbyl when W is O, and X-circle A-R1 is —S(O)2phenyl-R1, where R1 is H, C1-C3-hydrocarbyl or halogen.

### Claim 11 (depends on 10)

The compound or its pharmaceutically acceptable salt according to claim 10, wherein X is C(O), CH2, CD2, or SO2.

### Claim 12 (depends on 10)

The compound or its pharmaceutically acceptable salt according to claim 10, wherein W is NR7, S or O.

### Claim 13 (depends on 10)

The compound or its pharmaceutically acceptable salt according to claim 10, wherein circle A is selected from the group consisting of phenyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl (1,3,5-triazinyl, 1,2,4-triazinyl and 1,2,3-triazinyl), furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, naphthyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, isobenzothiophenyl, benzoxazolyl, benzisoxazole, quinolyl, isoquinolyl, quinazolyl, cinnolinyl, quinoxalinyl, naphthyridinyl, and benzopyrimidinyl.

### Claim 14 (depends on 10)

The compound or its pharmaceutically acceptable salt according to claim 10, wherein one of D and F is CH2.

### Claim 15 (depends on 10)

The compound or its pharmaceutically acceptable salt according to claim 10, wherein said compound corresponds in structure to a formula selected from the group consisting of:

### Claim 16 (depends on 3)

The compound or its pharmaceutically acceptable salt according to claim 3, wherein said compound corresponds in structure to Formula III
wherein D and F are the same or different and are CH2, CHD or CD2; each of m and n is one; and W, X, Z, Q, circle A, R1, R2 and the R groups therein defined are as described previously, except that i) one of Z and Q is C(O), and ii) W is other than NR2 or NR7 in which R2 and R7 is H or an aliphatic C1 hydrocarbyl when Z is C(O).

### Claim 17 (depends on 16)

The compound or its pharmaceutically acceptable salt according to claim 16, wherein X is C(O), CH2, CD2, or SO2.

### Claim 18 (depends on 16)

The compound or its pharmaceutically acceptable salt according to claim 16, wherein W is NR7, S or O.

### Claim 19 (depends on 16)

The compound or its pharmaceutically acceptable salt according to claim 16, wherein circle A is selected from the group consisting of phenyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl (1,3,5-triazinyl, 1,2,4-triazinyl and 1,2,3-triazinyl), furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, naphthyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, isobenzothiophenyl, benzoxazolyl, benzisoxazole, quinolyl, isoquinolyl, quinazolyl, cinnolinyl, quinoxalinyl, naphthyridinyl, and benzopyrimidinyl.

### Claim 20 (depends on 16)

The compound or its pharmaceutically acceptable salt according to claim 16, wherein one of Q and Z is C(O) and the other is CH2.

### Claim 21 (depends on 16)

The compound or its pharmaceutically acceptable salt according to claim 16, wherein said compound corresponds in structure to a formula selected from the group consisting of:

### Claim 22 (depends on 1)

The compound or its pharmaceutically acceptable salt according to claim 1 that corresponds in structure to Formula C, optionally including both individual enantiomeric forms, a racemate, diastereomers and mixtures thereof
wherein
G and W are selected from the group consisting of NR2, NR7, S and O, where R2 and R7 are the same or different and are H, C(H)v(D)h where each of v and h is 0, 1, 2 or 3 and v+h=3, C(H)q(D)r-aliphatic C1-C11 hydrocarbyl where each of q and r is 0, 1, or 2 and q+r=0, 1 or 2, aliphatic C1-C12 hydrocarbyl sulfonyl or aliphatic C1-C12 hydrocarboyl, with the provisos that:
i) one of G and W must be NR2 or NR7, and
ii) one of G and W is other than NR2 or NR7 in which R2 or R7 is H or an aliphatic C1 hydrocarbyl when (a) the sum of m+n is 1 and (b) the other of G and W is NR2 or NR7 bonded to a Z or Q, respectively, that is C(O).

### Claim 23 (depends on 22)

The compound or its pharmaceutically acceptable salt according to claim 22, wherein said compound corresponds in structure to a formula selected from the group consisting of:

### Claim 24 (depends on 22)

The compound or its pharmaceutically acceptable salt according to claim 22, wherein e and g are both zero.

### Claim 25 (depends on 24)

The compound or its pharmaceutically acceptable salt according to claim 24, wherein said compound corresponds in structure to Formula IV
wherein D and F are the same or different and are CH2, CHD or CD2; and W, X, Z, Q, circle A, R1, R2, R8 and the R groups therein defined are as described previously, except that i) W is other than NR2 or NR7 in which R2 or R7 is H or an aliphatic C1 hydrocarbyl when the sum of m+n is 1 and Z is C(O), and ii) R2 of the depicted NR2 group is other than H or an aliphatic C1 hydrocarbyl when the sum of m+n is 1, W is NR2 or NR7 and Q is C(O).

### Claim 26 (depends on 25)

The compound or its pharmaceutically acceptable salt according to claim 25, wherein X is C(O), CH2, CD2, or SO2.

### Claim 27 (depends on 25)

The compound or its pharmaceutically acceptable salt according to claim 25, wherein W is NR7, S or O.

### Claim 28 (depends on 25)

The compound or its pharmaceutically acceptable salt according to claim 25, wherein circle A is selected from the group consisting of phenyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl (1,3,5-triazinyl, 1,2,4-triazinyl and 1,2,3-triazinyl), furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, naphthyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, isobenzothiophenyl, benzoxazolyl, benzisoxazole, quinolyl, isoquinolyl, quinazolyl, cinnolinyl, quinoxalinyl, naphthyridinyl, and benzopyrimidinyl.

### Claim 29 (depends on 25)

The compound or its pharmaceutically acceptable salt according to claim 25, wherein one of Q and Z is C(O) and the other is CH2.

### Claim 30 (depends on 25)

The compound or its pharmaceutically acceptable salt according to claim 25, wherein said compound corresponds in structure to a formula:

### Claim 31 (depends on 22)

The compound or its pharmaceutically acceptable salt according to claim 22, wherein said compound corresponds in structure to Formula V
wherein D and F are the same or different and are CH2, CHD or CD2; and X, W, circle A, R1, R2 and the R groups therein defined are as described previously.

### Claim 32 (depends on 31)

The compound or its pharmaceutically acceptable salt according to claim 31, wherein X is C(O), CH2, CD2, or SO2.

### Claim 33 (depends on 31)

The compound or its pharmaceutically acceptable salt according to claim 31, wherein W is NR7, S or O.

### Claim 34 (depends on 31)

The compound or its pharmaceutically acceptable salt according to claim 31, wherein circle A is selected from the group consisting of phenyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl (1,3,5-triazinyl, 1,2,4-triazinyl and 1,2,3-triazinyl), furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, naphthyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, isobenzothiophenyl, benzoxazolyl, benzisoxazole, quinolyl, isoquinolyl, quinazolyl, cinnolinyl, quinoxalinyl, naphthyridinyl, and benzopyrimidinyl.

### Claim 35 (depends on 31)

The compound or its pharmaceutically acceptable salt according to claim 31, wherein one of D and F is CH2.

### Claim 36 (depends on 31)

The compound or its pharmaceutically acceptable salt according to claim 31, wherein said compound corresponds in structure to a formula:

### Claim 37 (depends on 22)

The compound or its pharmaceutically acceptable salt according to claim 22, wherein said compound corresponds in structure to Formula VI
wherein D and F are the same or different and are CH2, CHD or CD2; and each of m and n is one; W, X, Z, Q, circle A, R1, R2 and the R groups therein defined are as described previously, and each of m and n is 1, except that i) one of Z and Q is C(O), ii) W is other than NR2 or NR7 in which R2 or R7 is H or an aliphatic C1 hydrocarbyl when Z is C(O), and iii) R2 of the depicted NR2 group is other than H or an aliphatic C1 hydrocarbyl when W is NR2 or NR7, and Q is C(O).

### Claim 38 (depends on 37)

The compound or its pharmaceutically acceptable salt according to claim 37, wherein X is C(O), CH2, CD2, or SO2.

### Claim 39 (depends on 37)

The compound or its pharmaceutically acceptable salt according to claim 37, wherein W is NR7, S or O.

### Claim 40 (depends on 37)

The compound or its pharmaceutically acceptable salt according to claim 37, wherein circle A is selected from the group consisting of phenyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl (1,3,5-triazinyl, 1,2,4-triazinyl and 1,2,3-triazinyl), furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, naphthyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, isobenzothiophenyl, benzoxazolyl, benzisoxazole, quinolyl, isoquinolyl, quinazolyl, cinnolinyl, quinoxalinyl, naphthyridinyl, and benzopyrimidinyl.

### Claim 41 (depends on 36)

The compound or its pharmaceutically acceptable salt according to claim 36, wherein one of Q and Z is C(O) and the other is CH2.

### Claim 42 (depends on 37)

The compound or its pharmaceutically acceptable salt according to claim 37, wherein said compound corresponds in structure to a formula:

### Claim 43 (depends on 1)

A pharmaceutical composition comprising an analgesic effective amount of a compound of claim 1 dissolved or dispersed in a physiologically tolerable carrier.

### Claim 44 (depends on 2)

A pharmaceutical composition comprising an analgesic effective amount of a compound of claim 2 dissolved or dispersed in a physiologically tolerable carrier.

### Claim 45 (depends on 22)

A pharmaceutical composition comprising an analgesic effective amount of a compound of claim 22 dissolved or dispersed in a physiologically tolerable carrier

### Claim 46

A method of reducing one or both of inflammation and pain in a host mammal in need thereof that comprises administering to that host mammal a pharmaceutical composition containing an analgesic effective amount of a compound of Formula A or a pharmaceutically acceptable salt thereof, optionally including both individual enantiomeric forms, diastereomers and mixtures thereof dissolved or dispersed in a physiologically tolerable carrier
wherein
Q is CHR9 or C(O);
Z is CHR10 or C(O), but only one of Q and Z is C(O);
each of m and n is zero or one and the sum of m+n is 1 or 2;
G, P and W are selected from the group consisting of NR20, NR2, NR7, S and O, where R7 and R2 are the same or different and are H, C(H)v(D)h where each of v and h is 0, 1, 2 or 3 and v+h=3, C(H)q(D)r-aliphatic C1-C11 hydrocarbyl where each of q and r is 0, 1, or 2 and q+r=0, 1 or 2, aliphatic C1-C12 hydrocarbyl sulfonyl or aliphatic C1-C12 hydrocarboyl, and R20 is X-circle A-R1 as defined hereinafter, with the provisos that
i) only one of G, P and W is NR20,
ii) one of G, P and W must be NR20,
iii) P is NR2 when other than NR20,
iv) one of G and W is other than NR2 or NR7 in which R2 and R7 is H or an aliphatic C1 hydrocarbyl when (a) the sum of m+n is 1 and (b) the other of G and W is NR20, NR2, or NR7 bonded to a Z or Q, respectively, that is C(O); and
v) P is NR2 in which R2 is other than —S(O)2C1-C3-hydrocarbyl when (a) the sum of m+n is 1 and the Q or Z that is present is CH2, (b) the G or W that is not NR20 is O, and (c) R20 is —S(O)2phenyl-R1, where R1 is H, C1—O3-hydrocarbyl or halogen;
X is SO2, C(O), CH2, CD2, OC(O), NHC(NH) or NHC(O);
each of d, e, f and k is either zero or one and the sum of (d+e+f+k)=2, e is zero when d is zero, and k is zero when f is zero;
D and F are the same or different and are CH or CD;
E and K are the same or different and are CH2, CHD or CD2;
circle A is an aromatic or heteroaromatic ring system containing one ring or two fused rings;
R1 represents up to three substituent groups that themselves are the same or different, R1a, R1b, and R1c,
wherein each of those three groups, R1a-c, is separately selected from the group consisting of H, C1-C6 hydrocarbyl, C1-C6 hydrocarbyloxy, C1-C6 hydrocarbyloxycarbonyl, trifluoromethyl, trifluoromethoxy, C1-C7 hydrocarboyl, hydroxy-, trifluoromethyl- or halogen-substituted C1-C7 hydrocarboyl, C1-C6 hydrocarbylsulfonyl, C1-C6 hydrocarbyloxysulfonyl, halogen, nitro, phenyl, cyano, carboxyl, C1-C7 hydrocarbyl carboxylate, carboxamide or sulfonamide wherein the amido nitrogen in either group has the formula NR3R4 wherein R3 and R4 are the same or different and are H, C1-C4 hydrocarbyl, or R3 and R4 together with the depicted nitrogen form a 5-7-membered ring that optionally contains 1 or 2 additional hetero atoms that independently are nitrogen, oxygen or sulfur, MAr, where M is —CH2—, —O— or —N═N— and Ar is a single-ringed aryl or heteroaryl group, and NR5R6 wherein R5 and R6 are the same or different and are H, C1-C4 hydrocarbyl, C1-C4 acyl, C1-C4 hydrocarbylsulfonyl, or R5 and R6 together with the depicted nitrogen form a 5-7-membered ring that optionally contains 1 or 2 additional hetero atoms that independently are nitrogen, oxygen or sulfur;
R8, R9, and R10 are each H, or two of R8, R9, and R10 are H and one is a C1-C8 hydrocarbyl group that is unsubstituted or is substituted with up to three atoms that are the same or different and are oxygen or nitrogen atoms;
R11, R12, R13 and R14 are all H, or R11 and R13 are H and R12 and R14 are H or D, or one of the pair R11 and R12 or the pair R13 and R14 together with the depicted ring form a saturated or unsaturated 6-membered ring, and the other pair are each H or they are H and D as recited herein.

### Claim 47 (depends on 46)

The method according to claim 46, wherein said host mammal is selected from the group consisting of a primate, a laboratory rodent, a companion animal, and a food animal.

### Claim 48 (depends on 46)

The method according to claim 46, wherein said composition is administered a plurality of times over a period of days.

### Claim 49 (depends on 46)

The method according to claim 46, wherein said composition is administered a plurality of times in one day.

### Claim 50 (depends on 46)

The method according to claim 46, wherein said composition is administered perorally.

### Claim 51 (depends on 46)

The method according to claim 46, wherein said composition is administered parenterally.
